Fierce Healthcare April 19, 2024
The Biden administration has put the finishing touches on the steps entities covered under the 340B Drug Discount Program must take to resolve disputes with drug manufacturers.
The final rule issued by the Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) this week landed to the delight of hospital groups and frustration of the pharmaceutical industry.
A revision to the “policy and operational challenges” of the existing 340B Administrative Dispute Resolution (ADR) process outlined back in 2020, HHS said that its new approach is more streamlined and accessible to 340B entities of all sizes.
“HHS believes that for the ADR process to be workable, it needs to be accessible,” the department wrote in...
Today's Sponsors
Today's Sponsor